Brief: OPKO Health’S Modex Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study In Collaboration With Merck
07/01/2025 13:07
Jan 7 (Reuters) - Merck & Co Inc MRK.N :
* OPKO HEALTH’S MODEX THERAPEUTICS ANNOUNCES EPSTEIN-BARR
VIRUS
VACCINE CANDIDATE ENTERS PHASE I CLINICAL STUDY IN COLLABORATION
WITH MERCK
* MODEX THERAPEUTICS- DEVELOPMENT TRIGGERS UNDISCLOSED
MILESTONE
PAYMENT FROM MERCK
Source text: ID:nGNX2HjPby
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OPKO Health
See all newsOpko Health, Inc. Expected To Post A Loss Of 7 Cents A Share: Earnings Preview
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
US RESEARCH ROUNDUP-Bank7, Goldman Sachs, Morgan Stanley
Deals of the day-Mergers and acquisitions
US STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons